Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients ; volume:22 ; number:1 ; day:5 ; month:3 ; year:2022 ; pages:1-10 ; date:12.2022
BMC cancer ; 22, Heft 1 (5.3.2022), 1-10, 12.2022
- Urheber
-
Horimoto, Yoshiya
Ishizuka, Yumiko
Ueki, Yuko
Higuchi, Toru
Arakawa, Atsushi
Saito, Mitsue
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-09351-4
- URN
-
urn:nbn:de:101:1-2022060123384260948334
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:39 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Horimoto, Yoshiya
- Ishizuka, Yumiko
- Ueki, Yuko
- Higuchi, Toru
- Arakawa, Atsushi
- Saito, Mitsue
- SpringerLink (Online service)
Ähnliche Objekte (12)
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer